These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 25424534)

  • 1. Economic evaluation of arsenic trioxide for treatment of newly diagnosed acute promyelocytic leukaemia in Canada.
    Lachaine J; Mathurin K; Barakat S; Schuh AC
    Hematol Oncol; 2015 Dec; 33(4):229-38. PubMed ID: 25424534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic evaluation of arsenic trioxide compared to all-trans retinoic acid + conventional chemotherapy for treatment of relapsed acute promyelocytic leukemia in Canada.
    Lachaine J; Mathurin K; Barakat S; Couban S
    Eur J Haematol; 2015 Sep; 95(3):218-29. PubMed ID: 25354894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States.
    Tallman M; Lo-Coco F; Barnes G; Kruse M; Wildner R; Martin M; Mueller U; Tang B
    Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):771-7. PubMed ID: 26361645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Budgetary impact of treating acute promyelocytic leukemia patients with first-line arsenic trioxide and retinoic acid from an Italian payer perspective.
    Kruse M; Wildner R; Barnes G; Martin M; Mueller U; Lo-Coco F; Pathak A
    PLoS One; 2015; 10(8):e0134587. PubMed ID: 26267454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The economic research of arsenic trioxide for the treatment of newly diagnosed acute promyelocytic leukemia in China.
    Chen X; Hong Y; Zheng P; You X; Feng J; Huang Z; Wang Y
    Cancer; 2020 Jan; 126(2):311-321. PubMed ID: 31714584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
    Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z
    Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia.
    Lou Y; Qian W; Meng H; Mai W; Tong H; Tong Y; Huang J; Jin J
    Hematol Oncol; 2014 Mar; 32(1):40-6. PubMed ID: 23963734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incorporation of arsenic trioxide in induction therapy improves survival of patients with newly diagnosed acute promyelocytic leukaemia.
    Song X; Hu X; Lü S; Gao L; Chen L; Yang J; Zhang W; Wang J
    Eur J Haematol; 2014 Jul; 93(1):54-62. PubMed ID: 24592821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced medical costs and hospital days when using oral arsenic plus ATRA as the first-line treatment of acute promyelocytic leukemia.
    Jiang H; Liang GW; Huang XJ; Jiang Q; Han S; Shi LW; Zhu HH
    Leuk Res; 2015 Dec; 39(12):1319-24. PubMed ID: 26403986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
    Lo-Coco F; Avvisati G; Vignetti M; Thiede C; Orlando SM; Iacobelli S; Ferrara F; Fazi P; Cicconi L; Di Bona E; Specchia G; Sica S; Divona M; Levis A; Fiedler W; Cerqui E; Breccia M; Fioritoni G; Salih HR; Cazzola M; Melillo L; Carella AM; Brandts CH; Morra E; von Lilienfeld-Toal M; Hertenstein B; Wattad M; Lübbert M; Hänel M; Schmitz N; Link H; Kropp MG; Rambaldi A; La Nasa G; Luppi M; Ciceri F; Finizio O; Venditti A; Fabbiano F; Döhner K; Sauer M; Ganser A; Amadori S; Mandelli F; Döhner H; Ehninger G; Schlenk RF; Platzbecker U; ; ;
    N Engl J Med; 2013 Jul; 369(2):111-21. PubMed ID: 23841729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis of all-trans retinoic acid-linked arsenic trioxide treatment for acute promyelocytic leukemia.
    Chen L; Wang J; Hu X; Xu X
    Hematology; 2014 Jun; 19(4):202-7. PubMed ID: 24074286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial.
    Zhu HH; Wu DP; Jin J; Li JY; Ma J; Wang JX; Jiang H; Chen SJ; Huang XJ
    J Clin Oncol; 2013 Nov; 31(33):4215-21. PubMed ID: 24127444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia.
    Quezada G; Kopp L; Estey E; Wells RJ
    Pediatr Blood Cancer; 2008 Jul; 51(1):133-5. PubMed ID: 18293388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term prognosis of childhood acute promyelocytic leukaemia with arsenic trioxide administration in induction and consolidation chemotherapy phases: a single-centre experience.
    Cheng Y; Zhang L; Wu J; Lu A; Wang B; Liu G
    Eur J Haematol; 2013 Dec; 91(6):483-9. PubMed ID: 24033687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Ramaekers BLT; Riemsma R; Grimm S; Fayter D; Deshpande S; Armstrong N; Witlox W; Pouwels X; Duffy S; Worthy G; Kleijnen J; Joore MA
    Pharmacoeconomics; 2019 Jul; 37(7):887-894. PubMed ID: 30426463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Src family kinase inhibitor PP2 enhances differentiation of acute promyelocytic leukemia cell line induced by combination of all-trans-retinoic acid and arsenic trioxide.
    Jung YS; Cheong HJ; Kim SJ; Kim KH; Lee N; Park HS; Won JH
    Leuk Res; 2014 Aug; 38(8):977-82. PubMed ID: 24953245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of arsenic trioxide with or without all-trans retinoic acid for the treatment of acute promyelocytic leukemia: a meta-analysis.
    Wang H; Chen XY; Wang BS; Rong ZX; Qi H; Chen HZ
    Leuk Res; 2011 Sep; 35(9):1170-7. PubMed ID: 21774985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute promyelocytic leukemia with isochromosome 17q and cryptic PML-RARA successfully treated with all-trans retinoic acid and arsenic trioxide.
    Shepshelovich D; Oniashvili N; Parnes D; Klein A; Muchtar E; Yeshaya J; Aviram A; Rabizadeh E; Raanani P
    Cancer Genet; 2015 Nov; 208(11):575-9. PubMed ID: 26471811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term efficacy and safety of arsenic trioxide for first-line treatment of elderly patients with newly diagnosed acute promyelocytic leukemia.
    Zhang Y; Zhang Z; Li J; Li L; Han X; Han L; Hu L; Wang S; Zhao Y; Li X; Zhang Y; Fan S; Lv C; Li Y; Su Y; Zhao H; Zhang X; Zhou J
    Cancer; 2013 Jan; 119(1):115-25. PubMed ID: 22930197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of acute promyelocytic leukemia with arsenic trioxide: clinical results and open questions.
    Lengfelder E; Hofmann WK; Nowak D
    Expert Rev Anticancer Ther; 2013 Sep; 13(9):1035-43. PubMed ID: 24053202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.